Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology.
Ngo N, Choucair K, Creeden JF, Qaqish H, Bhavsar K, Murphy C, Lian K, Albrethsen MT, Stanbery L, Phinney RC, Brunicardi FC, Dworkin L, Nemunaitis J. Ngo N, et al. Among authors: choucair k. Future Oncol. 2019 Nov;15(33):3861-3876. doi: 10.2217/fon-2019-0374. Epub 2019 Oct 31. Future Oncol. 2019. PMID: 31668087 Review.
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
Metzinger MN, Verghese C, Hamouda DM, Lenhard A, Choucair K, Senzer N, Brunicardi FC, Dworkin L, Nemunaitis J. Metzinger MN, et al. Among authors: choucair k. Oncology. 2019;97(2):59-74. doi: 10.1159/000500488. Epub 2019 Jul 1. Oncology. 2019. PMID: 31261152 Review.
PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.
Willis O, Choucair K, Alloghbi A, Stanbery L, Mowat R, Charles Brunicardi F, Dworkin L, Nemunaitis J. Willis O, et al. Among authors: choucair k. Cancer Gene Ther. 2020 Sep;27(9):634-644. doi: 10.1038/s41417-020-0164-0. Epub 2020 Jan 28. Cancer Gene Ther. 2020. PMID: 31988478 Review.
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
Sliheet E, Robinson M, Morand S, Choucair K, Willoughby D, Stanbery L, Aaron P, Bognar E, Nemunaitis J. Sliheet E, et al. Among authors: choucair k. Cancer Gene Ther. 2022 Jul;29(7):993-1000. doi: 10.1038/s41417-021-00400-x. Epub 2021 Nov 16. Cancer Gene Ther. 2022. PMID: 34785763 Free PMC article. Clinical Trial.
32 results